PSA Screening: Evidence, Equity, and the Cost of Getting It Wrong
Recommended Citation
McLaughlin P. PSA Screening: Evidence, Equity, and the Cost of Getting It Wrong. Med Phys 2026; 53(5).
Document Type
Conference Proceeding
Publication Date
3-22-2026
Keywords
prostate specific antigen, conference abstract, drug combination, human, male, prostate cancer, screening
Publication Title
Med Phys
Abstract
Learning Objectives: Evaluate how prostate cancer disparities shape the population treated. Differentiate PSA screening claims from evidence (and quantify what benefit looks like). Explain why PSA screening guidance changed in 2012—and what that changed in the clinic.
Volume
53
Issue
5
COinS
